Juliana Mira Hernandez

Juliana Mira Hernandez

Auto-generated profile, based on publicly available information

Juliana Mira Hernandez

Department of Pharmacology, University of California, Davis, 451 Health Sciences Drive, Davis, CA, 95616, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 April 2024 in Cardiovascular Research
Verified
Journal Article
Open access
PDF file
JHJuliana Mira Hernandez
Juliana Mira Hernandez
ESErin Y Shen
Erin Y Shen
CKChristopher Y Ko
Christopher Y Ko
ZHZaynab Hourani
Zaynab Hourani
ESEmily R Spencer
Emily R Spencer
BHBence Hegyi
Bence Hegyi
Sex differences in heart failure with preserved ejection fraction (HFpEF) are important, but key mechanisms involved are incompletely understood. While animal models can inform about sex-dependent cellular and molecular changes, many previous pre-clinical HFpEF models have failed to recapitulate sex-dependent characteristics of human HFpEF. We tested for sex differences in HFpEF using a two-hit mouse model (leptin receptor–deficient db/db mice plus aldosterone infusion for 4 weeks; db/db + Aldo). We performed echocardiography, electrophysiology, intracellular Ca2+ imaging, and protein analysis. Female HFpEF mice exhibited more severe diastolic dysfunction in line with increased titin N2B isoform expression and PEVK element phosphorylation and reduced troponin-I phosphorylation. Female HFpEF mice had lower BNP levels than males despite similar comorbidity burden (obesity, diabetes) and cardiac hypertrophy in both sexes. Male HFpEF mice were more susceptible to cardiac alternans. Male HFpEF cardiomyocytes (vs. female) exhibited higher diastolic [Ca2+], slower Ca2+ transient decay, reduced L-type Ca2+ current, more pronounced enhancement of the late Na+ current, and increased short-term variability of action potential duration (APD). However, male and female HFpEF myocytes showed similar downregulation of inward rectifier and transient outward K+ currents, APD prolongation, and frequency of delayed afterdepolarizations. Inhibition of Ca2+/calmodulin-dependent protein kinase II (CaMKII) reversed all pathological APD changes in HFpEF in both sexes, and empagliflozin pre-treatment mimicked these effects of CaMKII inhibition. Vericiguat had only slight benefits, and these effects were larger in HFpEF females. We conclude that the db/db + Aldo pre-clinical HFpEF murine model recapitulates key sex-specific mechanisms in HFpEF and provides mechanistic insights into impaired excitation–contraction coupling and sex-dependent differential arrhythmia susceptibility in HFpEF with potential therapeutic implications. In male HFpEF myocytes, altered Ca2+ handling and electrophysiology aligned with diastolic dysfunction and arrhythmias, while worse diastolic dysfunction in females may depend more on altered myofilament properties.

6 December 2022 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
BHBence Hegyi
Bence Hegyi
JHJuliana Mira Hernandez
Juliana Mira Hernandez
CKChristopher Y. Ko
Christopher Y. Ko
JHJunyoung Hong
Junyoung Hong
ESErin Y. Shen
Erin Y. Shen
JBJulie Bossuyt
Julie Bossuyt
Background: The pathobiology of heart failure with preserved ejection fraction (HFpEF) is still poorly understood, and effective therapies remain limited. Diabetes and mineralocorticoid excess are common and important pathophysiological factors that may synergistically promote HFpEF. The authors aimed to develop a novel animal model of HFpEF that recapitulates key aspects of the complex human phenotype with multiorgan impairments. Methods and Results: The authors created a novel HFpEF model combining leptin receptor–deficient db/db mice with a 4‐week period of aldosterone infusion. The HFpEF phenotype was assessed using morphometry, echocardiography, Ca 2+ handling, and electrophysiology. The sodium‐glucose cotransporter‐2 inhibitor empagliflozin was then tested for reversing the arrhythmogenic cardiomyocyte phenotype. Continuous aldosterone infusion for 4 weeks in db/db mice induced marked diastolic dysfunction with preserved ejection fraction, cardiac hypertrophy, high levels of B‐type natriuretic peptide, and significant extracardiac comorbidities (including severe obesity, diabetes with marked hyperglycemia, pulmonary edema, and vascular dysfunction). Aldosterone or db/db alone induced only a mild diastolic dysfunction without congestion. At the cellular level, cardiomyocyte hypertrophy, prolonged Ca 2+ transient decay, and arrhythmogenic action potential remodeling (prolongation, increased short‐term variability, delayed afterdepolarizations), and enhanced late Na + current were observed in aldosterone‐treated db/db mice. All of these arrhythmogenic changes were reversed by empagliflozin pretreatment of HFpEF cardiomyocytes. Conclusions: The authors conclude that the db/db +aldosterone model may represent a distinct clinical subgroup of HFpEF that has marked hyperglycemia, obesity, and increased arrhythmia risk. This novel HFpEF model can be useful in future therapeutic testing and should provide unique opportunities to better understand disease pathobiology.

1 July 2023 in Journal of Equine Veterinary Science
Verified
Journal Article
Closed access
CBCristiana R. Bromberger
Cristiana R. Bromberger
JCJulia Rodrigues Costa
Julia Rodrigues Costa
MHMariana Herman
Mariana Herman
JHJuliana Mira Hernandez
Juliana Mira Hernandez
LALukas Garrido Albertino
Lukas Garrido Albertino
JOJose Oliveira-Filho
Jose Oliveira-Filho

1 February 2026 in American Journal of Physiology-Heart and Circulatory Physiology
Verified
Journal Article
Closed access
BHBence Hegyi
Bence Hegyi
LBLogan R. J. Bailey
Logan R. J. Bailey
JHJuliana Mira Hernandez
Juliana Mira Hernandez
CKChristopher Y. Ko
Christopher Y. Ko
ESErin Y. Shen
Erin Y. Shen
DBDonald Bers
Donald Bers
Excitation-Ca 2+ signaling-contraction coupling (ECC) mechanisms are fundamental to heart function. ECC mechanisms are differentially altered in murine models of heart failure with preserved ejection fraction (HFpEF) by dominant disease pathology and sex. Diastolic dysfunction is more pronounced in diabetic-obese HFpEF mice (worse in females) than in hypertensive-obese HFpEF mice (female sex is protective). Diabetic-obese mice and primarily hypertensive-obese HFpEF mice exhibit differential ECC alterations and largely distinctive transcription changes, providing mechanistic insights into HFpEF sub-phenogroups.

21 May 2026 in Basic Research in Cardiology
Verified
Journal Article
Open access
JHJuliana Mira Hernandez
Juliana Mira Hernandez
LBLogan R. J. Bailey
Logan R. J. Bailey
VSVictoria R. Salemme
Victoria R. Salemme
CKChristopher Y. Ko
Christopher Y. Ko
ESErin Y. Shen
Erin Y. Shen
BHBence Hegyi
Bence Hegyi
Effective treatments for heart failure with preserved ejection fraction (HFpEF) are limited. Empagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, provides cardiovascular benefits for patients with HFpEF. SGLT2 expression is virtually absent in cardiomyocytes, hence the exact protective mechanism of empagliflozin is unclear. We aimed to study the effect of in vivo empagliflozin treatment on excitation–contraction coupling (ECC), electrophysiology, and gene transcription in a translational two-hit HFpEF mouse model that combines the obese-diabetic leptin receptor-deficient db/db mice with chronic aldosterone infusion ( db/db + Aldo). We performed morphometry, echocardiography, cardiomyocyte electrophysiology, intracellular Ca 2+ imaging, and whole-heart RNA-sequencing in empagliflozin-treated db/db + Aldo and vehicle control mice. In db/db + Aldo mice, empagliflozin (in vivo, 4 weeks) reduced the elevated plasma blood glucose (13 ± 5 mmol/L versus 23 ± 8 mmol/L) and BNP levels, prevented pulmonary congestion, and ameliorated diastolic dysfunction. However, empagliflozin did not reduce cardiac hypertrophy and obesity. In healthy control mice, empagliflozin had no functional effect. Chronic in vivo empagliflozin treatment in db/db + Aldo also normalized the changes in cardiomyocyte electrophysiology and Ca 2+ handling properties measured in the absence of empagliflozin in the perfusion solution during cell experiments, indicating a true phenotypic rescue. Differentially expressed gene clusters were identified characteristic of the db/db genotype, aldosterone, and empagliflozin treatments. Interestingly, empagliflozin did not just reverse the HFpEF-altered gene expression but shifted it further away from control to a new expression profile. We conclude that chronic in vivo empagliflozin treatment restores cardiomyocyte electrophysiological and ECC properties, ameliorates diastolic function in cardiometabolic HFpEF, and induces complex gene expression changes.

30 March 2019 in Brazilian Journal of Veterinary Pathology
Verified
Journal Article
Closed access
LZLuiza Zakia1
Luiza Zakia1
MHMariana Herman
Mariana Herman
RBRoberta Basso
Roberta Basso
JHJuliana Hernadez
Juliana Hernadez
JJJoão Pessoa Araujo Jr.
João Pessoa Araujo Jr.
JOJose Oliveira-Filho
Jose Oliveira-Filho